Retension Pharmaceuticals (Ticker: RTSN US) is an American clinical-stage biotechnology company developing RTN-001, a once-daily oral treatment for uncontrolled and resistant hypertension. The company is evaluating RTN-001, its sole drug candidate, in a Phase 2b clinical trial that began in October 2025, with initial data expected in the first half of 2027.

Retension Pharmaceuticals plans to list on Nasdaq on October 9, 2026, offering 3.3 million shares at an indicated price range of $11 to $13 per share. At the $12 midpoint, the IPO would raise approximately $40 million and imply an estimated market capitalization of approximately $95 million.

The Delaware-incorporated company was founded in 2023 and reported no product revenue and a net loss of approximately $12 million for the 12 months ended June 30, 2026. Leerink Partners, Guggenheim Securities, Oppenheimer & Co. and Titan Partners are serving as joint managers for the offering.